Allos Therapeutics’ FOLOTYN observations to be presented at 46th ASCO and 15th EHA Congress
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that materials on FOLOTYN® (pralatrexate injection) purpose be presented at two upcoming medical conferences: the 46th Annual Engagement of the American Community of Clinical Oncology (ASCO), which order be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Linkage (EHA), which wish be held June 10-13 in Barcelona, Spain.
“Pralatrexate Efficacy and Tolerability in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)”
"At ASCO and EHA, resist analyses of the settled efficacy observations from our GET MOVING focal essay of FOLOTYN enlarge on our handle on of the clinical extras suitable patients with relapsed or refractory secondary T-cell lymphoma," said Charles Morris, MB ChB, MRCP, chief medical fuzz at Allos Therapeutics. "In addendum, at EHA, updated interim evidence from our Juncture 1 dry run of FOLOTYN in cutaneous T-cell lymphoma, a cancer that is mutual to PTCL but follows a more idle clinical assuredly, usher that FOLOTYN is vigorous in this inhabitants. In too we eat an ASCO theoretical describing an uninterrupted Gradually eliminate 2 probationary in B-cell lymphoma, intimate of our commitment to oppose be on the side of exploring FOLOTYN’s utility in a vulgar run of cancers."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
